Acquired Resistance to Therapy Network (ARTNet)

Official Account of @theNCI Acquired Resistance to Therapy Network (ARTNet).

[Acquired Resistance to Therapy Network (ARTNet) @NCIARTNet]

The Acquired Resistance to Therapy Network (ARTNet), of @theNCI focuses on mechanisms of acquired resistance to cancer therapies & disease recurrence and integrates those findings through team science. Learn more at https://t.co/aSe5ywa2Ei and https://t.co/WkJvOp2Ufn

[OHSU Knight Cancer Institute @OHSUKnight]

Dr. Brian Druker joined the Precision Signals podcast to discuss Gleevec, precision oncology, and the future of cancer research 🎙️

Listen: https://t.co/pV410De2wt

[Acquired Resistance to Therapy Network (ARTNet) @NCIARTNet]

🚀 Check this out — we’ve launched an AI for Cancer Webinar Catalog, updated weekly!
https://t.co/aqizWX56p7
This curated catalog brings together AI in cancer research webinars from publicly available academic, industry, and professional organizations in one place. A great resource for staying current with the rapidly evolving AI-oncology landscape.

[Acquired Resistance to Therapy Network (ARTNet) @NCIARTNet]

At today’s #ARTNetSCMeeting, co-chair Dr. Alan Hutson @Amherst73 of @RoswellPark provided network updates, and Dr. Ping Mu @PingMu_PhD of @YaleMed presented how his lab is leveraging AI tools to decode mechanisms of therapy resistance in prostate cancer.

[Acquired Resistance to Therapy Network (ARTNet) @NCIARTNet]

🎙️ The inaugural episode of the ARTNet Podcast is now live! Listen here and share with colleagues, friends, and family: https://t.co/4cqHd8irsz

Join moderator Dr. David Goodrich @RoswellPark
and featured speaker Dr. Jeffrey Tyner @OHSUKnight
as they discuss cancer resistance, tumor evolution, and ARTNet’s mission to advance collaborative resistance research in accessible, science-grounded language.

#ARTNet #NCI #CancerPlasticity #CancerAcquiredResistance #cancerfighter
@theNCI

[Cancer Cell @Cancer_Cell]

Cancer type-specific variation in patterns of driver alterations across 50,000 tumors https://t.co/PfCqPwXSNu

[Cancer Cell @Cancer_Cell]

JYP0322, a highly selective and brain-penetrant ROS1 inhibitor, overcomes ROS1G2032R resistance mutation in NSCLC: The first-in-human phase 1 trial https://t.co/USwsmDa97X

[NIH Innovates @NIH_Innovates]

Choosing the right research model is critical to advancing rigorous, reproducible science.

Learn how NIH supports the use of New Approach Methodologies (NAMs), including organoids, computational models, and real-world data: https://t.co/5k0gKBFZT5

[Acquired Resistance to Therapy Network (ARTNet) @NCIARTNet]

🎙️ The inaugural episode of the ARTNet Podcast is now live!

Join moderator Dr. David Goodrich @RoswellPark and featured speaker Dr. Jeffrey Tyner @OHSUKnight as they discuss cancer resistance, tumor evolution, and ARTNet’s mission to advance collaborative resistance research in accessible, science-grounded language.

Listen here and share with colleagues, friends, and family: https://t.co/usEtgqvYPo
#ARTNet #NCI #CancerPlasticity #CancerAcquiredResistance #cancerfighter @theNCI

[Acquired Resistance to Therapy Network (ARTNet) @NCIARTNet]

At today’s Functional Screens and Assays #ARTNetWGMeeting, Dr. Anton Windfelder @AntonGeorgeM from the Fraunhofer Institute for Molecular Biology shared fascinating research on host-pathogen interactions using caterpillars as a model organism. The presentation sparked a highly engaging discussion among participants. #ARTNet

[Acquired Resistance to Therapy Network (ARTNet) @NCIARTNet]

Congratulations to Dr. Jiang! @Dadi_Jiang

[Albert Koong, MD PhD @ACKoongMDPhD]

So proud of @Dadi_Jiang for winning the #radonc faculty research award and Dr. Fada Guan who won the faculty service award @utmdanderson. #EndCancer

[Acquired Resistance to Therapy Network (ARTNet) @NCIARTNet]

Join the conversation shaping the future of cancer care at the NCI workshop “Precision in Practice: A Functional Medicine Workshop” on July 1-2, 2026 at @theNCI Shady Grove Campus and online.
Day 1 will highlight the current state-of-the-art in functional precision medicine, featuring a keynote presentation by Dr. Anthony Letai @NCIDirector. Day 2 will focus on defining the key scientific questions that will shape the next decade of cancer care.
The workshop will bring together leaders from academia, industry, government, and patient advocacy to accelerate the translation of functional precision oncology into clinical practice.
Explore the draft agenda and register today:
https://t.co/YQEo8P1vDA

#CancerResearch #PrecisionMedicine #FunctionalPrecisionMedicine #Oncology #CancerCare

[Acquired Resistance to Therapy Network (ARTNet) @NCIARTNet]

We’re building a shared resource of free webinars on AI in cancer research, to support and empower our scientific community. 🧬🤖
If you know of any great sessions, please share the links in the comments and help grow this collective knowledge hub!

[Acquired Resistance to Therapy Network (ARTNet) @NCIARTNet]

New review just out in Nature Reviews Drug Discovery:
Drs. Erik S. Knudsen, Agnieszka K. Witkiewicz, and Sheheryar Kabraji of @RoswellPark outline the evolving landscape of CDK inhibition: from the success of CDK4/6 inhibitors in breast cancer to next-gen strategies expanding into other tumor types.
From combination therapies (HER2, PI3K) to CDK2 targeting and biomarker-guided patient selection, this piece captures where the field is heading a decade after first FDA approvals.
#CancerResearch #CDK #BreastCancer #TargetedTherapy

[Nature Reviews Drug Discovery @NatRevDrugDisc]

The evolving landscape of CDK inhibitor use in breast cancer therapy and beyond
https://t.co/jAQnkSQcVO
https://t.co/fTUpDKjAFo
This new Review discusses how combination strategies, novel CDK inhibitors and biomarkers are addressing drug resistance and expanding therapeutic uses

[Cancer Cell @Cancer_Cell]

Online Now: Dissecting the cellular architecture of breast cancer brain metastases reveals prognostically distinct immune landscapes https://t.co/twrojeCLkN

[National Cancer Institute @theNCI]

Today, we’re launching an initiative we’re calling #YourNCI that highlights how valuable the public investment in cancer research is – and how it pays off in cancer prevention, screening, diagnosis, survivorship and better, more effective treatments.

[Anirban Maitra @Aiims1742]

How Do Cancer Cells ‘Learn’ to Resist Treatment?
https://t.co/f1OOc02gOk
Congratulations to @ItaiYanai @nyulangone for his elegant @Nature paper today that made the cover!
https://t.co/mnJgpHEqjy
@Perlmutter_CC

[NIH @NIH]

🔬 NIH-supported scientists seek to better understand aggressive cancers by studying “organs-on-chips” – tiny, lab-built systems that mimic how human tissues function, and how the disease spreads.

These chips allow researchers to watch how cancer grows, moves, and responds to treatment in real time — down to how individual cells behave.

Read more about this @theNCI supported project ➡️ https://t.co/llkJHMtQWt

[Cell @CellCellPress]

In the latest issue! Hallmarks of cancer—Then and now, and beyond https://t.co/NZt79BwhDt